Histone Demethylase
The histones themselves, particularly H3 and H4, are subject to extensive chemical modifications such as phosphorylation, ubiquitination, acetylation, and methylation, which have profound effects on gene expression. The effects of histone methylation, which occurs primarily on arginines and lysines, depend on the site of modifi- cation, the extent of methylation, as well as on additional modifications on the same or neighboring histones. Misregulation of lysine demethylases is frequently observed in cancer, and the diverse natures of the regulatory defects indicate that cellular homeostasis requires a precise balance of histone methylation and demethylation. The first irrefutable evidence that methylation could be dynamically regulated came in 2004 with the discovery of the lysine-specific demethylase LSD1 (also known as KDM1A). Similar to monoamine oxidases (MAOs), LSD1 uses FAD as a cofactor to oxidize the methyl group and hydrolyze it toformaldehyde. LSD1 demethylates H3K4me1/2, but not H3K4me3, or other methylated lysinesin H3 such as H3K20me2. In prostate cancer cells, LSD1 also demethylates H3K9me1/2 when complexed to the androgen receptor, and other LSD1 variants have shown different substrate specificities. In AML, LSD1 represses differentiation markers such as E-cadherin.
Chemical or genetic inhibition of LSD1 results in differentiation of leukemia cells in vitro, and LSD1 has been suggested to regulate cancer stem cells. Loss of LSD1 expression in some breast cancers up-regulates transforming growthfactor b (TGF-b), promoting cellular invasion, whereas overexpression of KDM5B (PLU-1) represses genes that promote differentiation and maintenance of genome integrity, such as CAV-1 and BRCA-1. In prostate cancer, KDM4B overexpression promotes cell proliferation by targeting cell cycle regulators such as PLK and Aurora kinase A. Given the therapeutic potential of targeting histone methylation in cancer and other diseases, many research groups are pursuing the development of demethylase inhibitors.
References
1.Jambhekar A, et al. Cold Spring Harb Perspect Med. 2017;7(1):a026484.
Chemical or genetic inhibition of LSD1 results in differentiation of leukemia cells in vitro, and LSD1 has been suggested to regulate cancer stem cells. Loss of LSD1 expression in some breast cancers up-regulates transforming growthfactor b (TGF-b), promoting cellular invasion, whereas overexpression of KDM5B (PLU-1) represses genes that promote differentiation and maintenance of genome integrity, such as CAV-1 and BRCA-1. In prostate cancer, KDM4B overexpression promotes cell proliferation by targeting cell cycle regulators such as PLK and Aurora kinase A. Given the therapeutic potential of targeting histone methylation in cancer and other diseases, many research groups are pursuing the development of demethylase inhibitors.
References
1.Jambhekar A, et al. Cold Spring Harb Perspect Med. 2017;7(1):a026484.
Chromatin/Epigenetic
Histone Demethylase
-
KDM1A-IN-29
产品货号 : M37602
cas no: 1423715-30-3
KDM1A-IN-29 is a histone demethylase inhibitor. -
P3FI-63
产品货号 : M37503
cas no: 931596-95-1
P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers. -
LSD1-IN-30
产品货号 : M37358
cas no: 1289575-45-6
LSD1-IN-30 (compound 3) 是赖氨酸特异性脱甲基酶 1 (LSD1) 的有效抑制剂,IC50 值为 0.291 μM。 -
LSD1-IN-27
产品货号 : M37006
cas no: 2904571-94-2
LSD1-IN-27 (Compound 5ac) 是一种 LSD1 抑制剂 (IC50: 13 nM)。LSD1-IN-27 抑制胃癌细胞的干细胞性和迁移。LSD1-IN-27 还可降低 BGC-823 和 MFC 细胞中 PD-L1 的表达。LSD1-IN-27 可增强对胃癌的 T 细胞免疫反应。 -
Zavondemstat
产品货号 : M36329
cas no: 1851412-93-5
Zavondemstat (QC8222; TACH 101) 是一种组蛋白赖氨酸脱甲基酶 4D (KDM4D) 抑制剂,具有抗肿瘤活性。